Plain-English translation of NCT07020221 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called that targets a specific genetic mutation found in some advanced cancers. The medication will be tested on its own and also combined with other cancer treatments to see how safe and effective it is. Researchers want to find the best dose and understand how well this treatment works for people with cancers like pancreatic cancer, lung cancer, and colorectal cancer that have this particular genetic change.
Many advanced cancers have a genetic mutation called KRAS G12D that makes them difficult to treat with standard therapies. This trial exists because researchers believe this new medication could block the effects of this mutation and help slow or stop cancer growth where other treatments have not worked well enough.
You likely qualify if…
You likely don't qualify if…
Participants will take the medication by mouth daily as part of an outpatient study, with regular visits to the clinic for check-ups, blood tests, and imaging scans to monitor how the cancer is responding and check for side effects. Depending on which treatment group they join, they may receive the medication alone or in combination with other established cancer drugs. The study involves both a dose-finding phase (to determine the safest and most effective dose) and an expansion phase to confirm how well the treatment works.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States